Tom 3, Nr 4 (2022)
Opis przypadku
Opublikowany online: 2023-03-20
Wyświetlenia strony 344
Wyświetlenia/pobrania artykułu 5
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Zastosowanie infliksimabu jako III linii leczenia sarkoidozy — analiza kliniczna 3 przypadków

Karol Bączek1, Joanna Miłkowska-Dymanowska1, Jerzy Marczak1, Wojciech Piotrowski1
Pneum Pol 2022;3(4):131-139.

Streszczenie

Brak

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Thillai M, Atkins CP, Crawshaw A, et al. BTS Clinical Statement on pulmonary sarcoidosis. Thorax. 2021; 76(1): 4–20.
  2. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999; 160(2): 736–755.
  3. Judson MA, Thompson BW, Rabin DL, et al. ACCESS Research Group. The diagnostic pathway to sarcoidosis. Chest. 2003; 123(2): 406–412.
  4. Baughman RP, Judson MA, Wells A. The indications for the treatment of sarcoidosis: Wells Law. Sarcoidosis Vasc Diffuse Lung Dis. 2017; 34(4): 280–282.
  5. Baughman RP, Teirstein AS, Judson MA, et al. Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001; 164(10 Pt 1): 1885–1889.
  6. Mañá J, Rubio-Rivas M, Villalba N, et al. Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: Cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain. Medicine (Baltimore). 2017; 96(29): e7595.
  7. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021; 58(6).
  8. Judson MA, Chaudhry H, Louis A, et al. The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respir Med. 2015; 109(4): 526–531.
  9. Baughman RP, Drent M, Kavuru M, et al. Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006; 174(7): 795–802.
  10. Baughman RP, Judson MA, Lower EE, et al. Sarcoidosis Investigators. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis. 2016; 32(4): 289–295.
  11. Drent M, Cremers JP, Jansen TL, et al. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014; 31(2): 91–107.